Repros' FDA meeting goes well, shares soar

After meeting with the FDA to discuss Phase 3 trial data requirements for the use of its Androxal drug to treat secondary hypogonadism, Repros Therapeutics (RPRX +12.9%) says it "expects to maintain its timeline for submitting an NDA prior to the end of 2014."

Repros adds it "understands that the safety of Androxal will stand on its own merits during NDA review and no additional safety assessments are currently planned prior to NDA submission."

Shares plunged in October after FDA guidance raised doubts about the timing of Androxal's NDA submission.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs